Literature DB >> 25973053

Assessing methylation status of PAX1 in cervical scrapings, as a novel diagnostic and predictive biomarker, was closely related to screen cervical cancer.

Jun Xu1, Ling Xu1, Baohua Yang1, Lifeng Wang1, Xiao Lin1, Hong Tu2.   

Abstract

OBJECTIVE: Previous studies have demonstrated that levels of hypermethylation of paired boxed gene 1 in cervical tissues are associated with the grades of severities of cervical neoplasia in women, which suggests that testing for DNA methylation has a potential role in neoplasma screening. In this study, by testing methylation levels of PAX1 genes in cervical scrapings and cervical tissues of different lesion levels, aims to evaluate the diagnostic value of DNA methylation testing as a biomarker for early detecting cancerous changes in cervical tissues and to compare the efficacy between PAX1 methylation test and HPV test in detecting of cervical cancer.
METHODS: A total of 121 cervical scrapings were analyzed, including normal (n = 28), cervical intraepithelial neoplasm 1 (CIN1; n = 32), CIN2/3 (n = 34), and invasive cancer (n = 27), which were all diagnosed by pathologic examination.
RESULTS: The values of PAX1 methylation reference in invasive cancer (mean [SE], 26.3 [3.5]) was significantly higher than CIN2/3 (13. 2 [2.2]) and the CIN1 (4.5 [0.45]; P < 0.001). The PAX1 promoter was hypermethylated in 100% of invasive cancer tissue compared with 0% of normal tissue, 9% of CIN1, 44% of CIN2/3 (P < 0.01). Methylation levels of cervical scrapings and cervical tissues represent strong consistency within each group. In contrast, the HPV test result was positive in 17% of normal tissue, 81% of CIN1, 91% of CIN2/CIN3, and 92% of invasive cancer. Based on receiver operating characteristic (ROC) analysis, hypermethylation of PAX1 was a significant candidate in segregating cervical cancer from normal/cervical neoplasia cases (P < 0.001). At an optimal cutoff value, sensitivity and specificity between 80% and 93% were obtained. In conclusion, the current results indicated that the methylation density of PAX1 by pyrosequencing in cervical scrapings held a great promise for cervical cancer screening.

Entities:  

Keywords:  HPV; PAX1; bisulfate pyrosequencing; cervical cancer; methylation

Mesh:

Substances:

Year:  2015        PMID: 25973053      PMCID: PMC4396293     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  Breast and cervical cancer in 187 countries between 1980 and 2010.

Authors:  J Ferlay; D Forman; C D Mathers; F Bray
Journal:  Lancet       Date:  2012-04-14       Impact factor: 79.321

2.  PAX1 methylation analysis by MS-HRM is useful in triage of high-grade squamous intraepithelial lesions.

Authors:  Zhen-Ming Wang
Journal:  Asian Pac J Cancer Prev       Date:  2014

Review 3.  HPV detection methods and genotyping techniques in screening for cervical cancer.

Authors:  Maj Liv Eide; Hervé Debaque
Journal:  Ann Pathol       Date:  2012-11-22       Impact factor: 0.407

4.  Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.

Authors:  Jo-Heon Kim; Yoo Duk Choi; Ji Shin Lee; Jae Hyuk Lee; Jong Hee Nam; Chan Choi
Journal:  Gynecol Oncol       Date:  2010-01       Impact factor: 5.482

5.  Mutations in PAX1 may be associated with Klippel-Feil syndrome.

Authors:  J M McGaughran; A Oates; D Donnai; A P Read; M Tassabehji
Journal:  Eur J Hum Genet       Date:  2003-06       Impact factor: 4.246

6.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

7.  An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.

Authors:  Her-Young Su; Hung-Cheng Lai; Ya-Wen Lin; Yu-Ching Chou; Chin-Yu Liu; Mu-Hsien Yu
Journal:  Int J Cancer       Date:  2009-01-15       Impact factor: 7.396

Review 8.  2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.

Authors:  Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon
Journal:  Am J Obstet Gynecol       Date:  2007-10       Impact factor: 8.661

9.  Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells.

Authors:  Yi Zhang; Fu-qiang Chen; Ye-hong Sun; Shu-yan Zhou; Ti-yuan Li; Rui Chen
Journal:  J Exp Clin Cancer Res       Date:  2011-10-17

Review 10.  Epigenetic alteration and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Front Genet       Date:  2013-12-03       Impact factor: 4.599

View more
  7 in total

1.  Quantitative DNA methylation analysis of paired box gene 1 and LIM homeobox transcription factor 1 α genes in cervical cancer.

Authors:  Ling Xu; Jun Xu; Zheng Hu; Baohua Yang; Lifeng Wang; Xiao Lin; Ziyin Xia; Zhiling Zhang; Yunheng Zhu
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

2.  PAX1 and SOX1 methylation as an initial screening method for cervical cancer: a meta-analysis of individual studies in Asians.

Authors:  Yan Chen; Zhaolei Cui; Zhenzhou Xiao; Minhua Hu; Chuanhui Jiang; Yingying Lin; Yansong Chen
Journal:  Ann Transl Med       Date:  2016-10

Review 3.  The Progress of Methylation Regulation in Gene Expression of Cervical Cancer.

Authors:  Chunyang Feng; Junxue Dong; Weiqin Chang; Manhua Cui; Tianmin Xu
Journal:  Int J Genomics       Date:  2018-04-16       Impact factor: 2.326

Review 4.  The promising role of PAX1 (aliases: HUP48, OFC2) gene methylation in cancer screening.

Authors:  Chao Fang; Sai-Ying Wang; Yu-Ligh Liou; Ming-Hua Chen; Wen Ouyang; Kai-Ming Duan
Journal:  Mol Genet Genomic Med       Date:  2019-01-12       Impact factor: 2.183

5.  Paired Box-1 (PAX1) Activates Multiple Phosphatases and Inhibits Kinase Cascades in Cervical Cancer.

Authors:  Po-Hsuan Su; Hung-Cheng Lai; Rui-Lan Huang; Lin-Yu Chen; Yu-Chi Wang; Tzu-I Wu; Michael W Y Chan; Chi-Chun Liao; Chien-Wen Chen; Wei-Yu Lin; Cheng-Chang Chang
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

6.  Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis.

Authors:  Helen Kelly; Yolanda Benavente; Miquel Angel Pavon; Silvia De Sanjose; Philippe Mayaud; Attila Tibor Lorincz
Journal:  Br J Cancer       Date:  2019-10-16       Impact factor: 7.640

Review 7.  DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment.

Authors:  Hongming Zhu; He Zhu; Miao Tian; Dongying Wang; Jiaxing He; Tianmin Xu
Journal:  Front Genet       Date:  2020-04-09       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.